Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

BG Medicine wants to fill big gaps in diagnostic medicine. The biosciences researcher primarily provides drug research and development services to such top global pharmaceutical makers as Pfizer and AstraZeneca, US government agencies, and to the health care product divisions of companies like Mitsubishi. BG Medicine specializes in developing biomarkers, substances used to detect disease at a molecular level, that enable research into the causes of disease and the effectiveness of drugs used to treat them. Products in the planning and discovery stages include molecular diagnostic tests for heart disease, neurological disorders, and cancer.

MediGene develops drugs that save lives or just make life easier. Spun off from the Munich Gene Center in 1994, MediGene focuses its R&D efforts on therapies that battle various forms of cancer and autoimmune conditions. It also has several drugs on the market, many of them sold through partnerships with other drug firms. The company's Eligard treatment for prostate cancer is sold in Europe by Astellas Pharma, and its Veregen ointment for genital warts is on the US market (Bradley Pharmaceuticals (now part of Nycomed US) sells the drug). In 2008 MediGene won approval from European regulatory authorities for Oracea, a treatment for rosacea; it sold European marketing rights for the drug to Galderma Laboratories.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.

Celgene Corporation company was founded in 1980 and is headquartered in Summit, New Jersey. Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum.Celgene Corporation company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer.

Capellon was founded in 1999. Capellon Pharmaceuticals is helping curb the common cold. Capellon Pharmaceuticals company's product portfolio includes Liquibid, Rescon, and Tussi-bid, prescription remedies for cough and congestion. Other products target various allergies as well as respiratory, gastrointestinal, and bladder ailments. Capellon concentrates its efforts on marketing products it already has and acquiring products useful to it current customer base. With an intense focus on growth it looks for partners with whom it can co-promote new drugs whenever possible.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Expression Analysis isn't run by body language specialists, but when researchers need DNA analyzed, they can turn to Expression Analysis. The company provides outsourced microarray processing, genotyping, RNA amplification and isolation, and other data generation and analysis services. The company uses gene research platforms developed by companies including Affymetrix, Life Technologies, and Illumina. It analyzes a variety of samples including whole blood, tissue cells, and frozen samples, for customers including government agencies and pharmaceutical development firms.

Amarillo Biosciences, Inc. company was founded in 1984 and is based in Amarillo, Texas. Amarillo Biosciences, Inc. (AMAR) is engaged in developing biologics for the treatment of human and animal diseases. The Company has a technology for a less toxic method of administration, low-dose oral interferon, in United States Food and Drug Administration (FDA) Phase II clinical trials. The Company has developed a dietary supplement and an interferon alpha lozenge, but, as of December 31, 2008, had not commenced any product commercialization activities. Injectable interferon is an immune modulator used to treat viral and autoimmune diseases and cancer. Orally delivered interferon binds to mucosal cells in the mouth and throat resulting in stimulation of immune mechanisms, and has been shown to activate hundreds of immune system genes in the peripheral blood. As of December 31, 2008, the Company has a Phase II study in progress in the United States to treat oral warts in human immunodeficiency virus-positive (HIV+) patients (Orphan Drug Designation).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.